With the R&D and manufacture of controlled-release drug products as the core business, Anbison focuses on development of high-end controlled-release dosage forms and finished dosage forms that are inherently difficult to manufacture. Meanwhile, we are actively expanding to 505b(2) drugs and complex long-acting injectables.

To learn more, please slide the window left and right

Product Name Status 2022 2023 2024 2025
Topiramate Extended-release Capsules Submitted to NMPA
Levetiracetam extended-release Granule Submitted to NMPA
Mesalamine Extended Release Capsules Submitted to NMPA/FDA
Mesalazine gastro-resistant prolonged-release granules Submitted to NMPA
Mesalazine Enteric-coated Tablets(Gsatro Resistant Prolonged Release) Submitted to NMPA
Compound Sodium Valproate and Valproic Acid Sustained Release Tablets Submitted to NMPA
Agomelatine Tablets Submitted to NMPA
Exemestane Tablets Submitted to NMPA
Flurbiprofen Cataplasms Submitted to NMPA
Amlodipine and Benazepril Hydrochloride Capsules Submitted to NMPA
Cytarabine for Injection Submitted to NMPA
Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Submitted to NMPA
Benidipine Hydrochloride Tablets Submitted to NMPA
Mesalazine Suppositories Submitted to NMPA
Pranoprofen Eye Drops Submitted to NMPA
Tafluprost Eye Drops Submitted to NMPA
Cyclosporin Eye Drops/cyclosporine ophthalmic emulsion Submitted to FDA
中文有码vs人妻_五月婷婷激色号网_日本久久一区一本高清_日本伊人色综合网